In mid-August 2026, Syrian authorities arrested businessman and director of al-Qanawati Pharmaceutical Industries, Rafiq al-Qanawati, who is currently under investigation regarding the use of the precursor chemical "pseudoephedrine" to manufacture narcotics in his factory. This followed the Anti-Illicit Gains Commission's seizure last July of the al-Qanawati pharmaceutical plant in Jdeidat Artouz, Damascus, as part of investigations related to its owner. If the investigations substantiate these suspicions, the case will not merely represent a violation committed by a single factory; rather, it will reveal the continued potential for exploiting licensed pharmaceutical facilities and drug precursors as a front for narcotics production.
Recently, Syria's Anti-Narcotics Department announced the interception of an attempt to smuggle a large shipment of narcotics into Jordan, amid recurrent reports of similar thwarted attempts across the Syrian border. While these operations do not necessarily prove that all shipments were manufactured inside Syria, they indicate that Syrian territory remains part of regional drug trafficking routes, despite the Syrian Ministry of Interior's announcement on 4 June 2025—following the fall of the Assad regime—of the seizure of all Captagon pill production laboratories, whose manufacturing and smuggling had been widespread during the former regime's rule. The persistence of smuggling attempts suggests that dismantling known production sites was not sufficient to halt this activity, as financing, supply, transport, and distribution networks are far more adaptable and capable of repositioning than fixed manufacturing facilities.
These concerns are compounded by reports, based on journalistic investigations, that the Ministry of Health granted a new license for the manufacture of human pharmaceuticals to an individual accused of involvement in Captagon production during the Assad regime era. Documents from 2017 anti-narcotics archives revealed that Ghaith al-Ansari led a network that embezzled pseudoephedrine intended for pharmaceutical manufacturing and sold it on the black market for Captagon production. The network also concealed the shortfall in raw materials by grinding "Decostamin" pills and re-pressing them into other pharmaceutical packaging, routing transactions through warehouses in Damascus, Aleppo, and Tartous, whose owners signed fictitious receipt invoices to cover up the diversion of active pharmaceutical ingredients. If the reports regarding the granting of a new license to him are true, it points to flaws in vetting investor backgrounds and in information sharing among health, security, and regulatory authorities, thereby allowing individuals with past suspicions to be reintegrated into the legitimate pharmaceutical sector.
Pharmaceutical manufacturing in Syria is considered an economically and strategically vital productive sector, given the jobs and investments it provides and its role in achieving pharmaceutical security and reducing import dependency. The sector also serves as a nucleus for complementary industries and services, such as packaging, medical equipment manufacturing, transportation, storage, and applied scientific research. Therefore, revitalizing pharmaceutical industries does not merely mean increasing drug production; it can also contribute to stimulating a broader chain of industrial activities, striking a greater balance between health and economic security, and positioning Syria in the long term to compete in regional markets, particularly in biologics and biopharmaceuticals.
Nevertheless, Syrian pharmaceutical exports have fallen to approximately $40 million, with export markets limited to only 23 countries, reflecting the sector's diminished productive capacity and competitiveness compared to past levels. The industry is navigating a critical phase between recovery efforts following long years of war and economic and logistical hardships hindering factory operations. Key challenges include difficulties in securing raw materials essential for production and their high cost on global markets, which directly impacts drug prices in the domestic market. The war also caused extensive damage to infrastructure; several factories were partially or completely destroyed, and much of the machinery and equipment was rendered inoperable, making the restoration of production contingent on securing financing, equipment, energy, and supply chains, rather than merely reissuing licenses.
The industry also faces regulatory challenges and legal impediments that constrain its ability to recover. The Ministry of Health imposed dollar-denominated fees on local pharmaceutical manufacturers, increasing production costs and impacting the prices of domestic medicines. At the same time, an open-import policy has led to the proliferation of imported pharmaceuticals in pharmacies and markets at competitive prices and quality, placing local products at an uneven disadvantage and prompting segments of consumers to favor imported alternatives. Consequently, the pharmaceutical sector operates within an environment compounded by rising costs, shortages of certain essential medicines, declining purchasing power, and weak export capabilities, threatening the exit of additional factories from the market if these imbalances are left unaddressed.
Yet the risks of this environment are not confined to the contraction of legitimate production. Weak oversight over dual-use pharmaceutical chemicals, combined with financial pressures facing manufacturers, could create loopholes exploited by drug networks to acquire precursor materials or use licenses, warehouses, and import/export channels as a cover for their illicit activities. This does not mean that the distress of pharmaceutical industries automatically leads factories into drug production, but it increases their vulnerability to infiltration, especially when financial strain coincides with lax investor vetting and the absence of robust tracking systems.
If current conditions persist without a comprehensive solution, the recovery of the pharmaceutical industry will remain constrained, while opportunities to exploit legitimate facilities for illicit activities will increase. Moreover, the return of individuals previously linked to the Captagon trade to conducting business through licensed factories—if confirmed—indicates that dismantling the visible structure of this trade was not necessarily accompanied by the dismantling of its financial and administrative networks and ties within state institutions. Thus, the danger lies not only in the establishment of new clandestine laboratories, but also in the potential reactivation of certain legacy production and supply loops from within the legal sector, damaging the reputation of the Syrian pharmaceutical industry, undermining its export prospects, and posing severe security and health ramifications.
Ultimately, the future of the Syrian pharmaceutical industry depends on the state's ability to pursue two parallel tracks: creating a productive environment that helps legitimate factories survive and recover, and developing a regulatory framework that prevents their exploitation in Captagon production or the supply of its precursor chemicals. The first track requires lowering fees on essential materials, supporting the rehabilitation of factories, and encouraging investment and exports; the second requires tightening background checks on licensees and warehouse operators, enhancing coordination between the Ministries of Health and Interior alongside regulatory bodies, and establishing a tracking system for dual-use pharmaceutical materials from the point of import through to the finished product.
Accordingly, the battle to dismantle Captagon networks is still in its early stages. Seizing laboratories and shipments addresses only the immediate manifestations of the activity, whereas the deeper challenge lies in dismantling the economic, logistical, and administrative networks that operated under official cover during the Assad regime era. Without dismantling these networks and blocking their renewed access to factories, licenses, and pharmaceutical trade channels, attempts to revive the industry could inadvertently become an opportunity to rebuild parts of the Captagon economy.